Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data.

In controlled periods of the clinical trials, abatacept-treated patients had similarly low rates of OIs compared with placebo-treated patients. Overall, OI rates were similar among abatacept-treated patients in the controlled and cumulative periods and consistent with the ranges reported in the literature.